Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to determine whether denosumab (an FDA-approved osteoporosis
therapy), in combination with teriparatide (an FDA-approved osteoporosis therapy), will
increase bone mineral density more than either one alone in postmenopausal osteoporotic
women.